New pre-surgery treatment tailored to cancer markers in mouth cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your cancer is confirmed as oral squamous cell carcinoma (mouth/throat areas like tongue, gums, inner cheek, or hard palate)
- Your cancer is stage III or stage IVA with no spread to distant organs (M0)
- Your tumor has a PD-L1 “combined positive score” higher than 10
- Your general health is good enough for study treatment (ECOG score 0 to 2)
- You can safely take study medicines based on recent blood tests, heart/liver/kidney health, and infection status
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help treat advanced mouth cancer. It aims to shrink tumors and improve outcomes.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
This trial studies whether giving anti–PD-1 immunotherapy together with chemotherapy before surgery can improve outcomes for people with locally advanced, operable oral squamous cell carcinoma. It aims to shrink the cancer and make surgery more effective by treating both the tumor and the immune response.
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
This trial tests two newer drugs (one targeted therapy, one immunotherapy) given before surgery to shrink mouth cancer and improve outcomes. The goal is to see if combining them is safe and effective for people with stage III-IVA disease.
Hear when a new Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.